| dc.description.abstract | One of the most commonly isolated foodborne pathogens is Salmonella. More than 2500
Salmonella serotypes have been recognized so far, and more than half of them are
associated with Salmonella enterica subsp. enterica. The development of multi – drug
resistant (MDR) Salmonella serotypes is also having a substantial influence on the
effectiveness of antibiotic therapy, and an increase in the prevalence of MDR strains may
enhance the mortality rates associated with Salmonella infections. This study would
evaluate the multi – drug resistant rate and determine the resistant factors of Salmonella
enterica serotype Kentucky (S. kentucky) 1067 on both genome and plasmids. Plasmids
carrying resistant genes were isolated from S. kentucky 1067 using alkaline lysis method
and were transformed into E. coli JM109. For the antibiotic susceptibility test, disk
diffusion method was used for the determination of the multi – drug resistant phenotype
of S. kentucky 1067 via transformed E. coli with five different antibiotics. Whole genome
sequencing analysis was applied for the detection of resistant factors of the antibiotic –
resistant S. kentucky 1067 isolates. S. kentucky 1067 was recorded to resist all five tested
antibiotics including Ampicillin (AM), Amoxicillin (AMX), Ciprofloxacin (CIP),
Tetracycline (TE), and Gentamicin (GN). Besides, 100% transformed E. coli clones were
shown their resistance to AM. The proportion of E. coli containing plasmids extracted
from Salmonella that resisted to at least two antibiotics was 83.33%, mainly for AM and
CIP. Otherwise, MobC protein was also determined to express in plasmid of S. kentucky
1067. In this study, a great number of antibiotic resistance genes in Salmonella kentucky
1067 were identified based on WGS analysis. More importantly, besides the presence of
these antibiotic resistance genes, the resistant factors also appeared in plasmids of S.
kentucky 1067. Therefore, understand thoroughly the characteristics of these plasmids
would make a significant contribution in the future | en_US |
